Fig. 4

Scenario of cardiorenal effects SGLT-2i in patients with T2D participating in CVOTs. MACE, major adverse cardiovascular events; DKD, diabetic kidney disease. : modest benefit (the hazard ratio -HR- for a given endpoint during treatment with a gliflozin is > 0.85 and < 1.0, as compared with placebo). : moderate benefit (HR ≤ 0.85 and > 0.75). : large benefit (HR ≤ 0.75)